Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction
- 25 January 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 39 (3) , 377-386
- https://doi.org/10.1016/s0735-1097(01)01758-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary InterventionCirculation, 2001
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind studyPublished by Oxford University Press (OUP) ,2000
- Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial InfarctionCirculation, 2000
- Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial InfarctionCirculation, 2000
- Abciximab Facilitates the Rate and Extent of ThrombolysisCirculation, 1999
- A Clinical Trial Comparing Primary Coronary Angioplasty with Tissue Plasminogen Activator for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- TIMI Frame CountCirculation, 1996
- Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarctionJournal of the American College of Cardiology, 1994
- The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1993